• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Sorour, O., Elearyan, E., Tahoun, M., Hamad, S. (2023). COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB. ALEXMED ePosters, 5(4), 36-37. doi: 10.21608/alexpo.2023.248931.1731
Osama Ahmed Saad Allah Sorour; Eman Moahmed Elearyan; Mona Moustafa Tahoun; Salma Ali Hamad. "COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB". ALEXMED ePosters, 5, 4, 2023, 36-37. doi: 10.21608/alexpo.2023.248931.1731
Sorour, O., Elearyan, E., Tahoun, M., Hamad, S. (2023). 'COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB', ALEXMED ePosters, 5(4), pp. 36-37. doi: 10.21608/alexpo.2023.248931.1731
Sorour, O., Elearyan, E., Tahoun, M., Hamad, S. COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB. ALEXMED ePosters, 2023; 5(4): 36-37. doi: 10.21608/alexpo.2023.248931.1731

COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB

Article 1, Volume 5, Issue 4, December 2023, Page 36-37  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.248931.1731
View on SCiNiTO View on SCiNiTO
Authors
Osama Ahmed Saad Allah Sorour1; Eman Moahmed Elearyan2; Mona Moustafa Tahoun3; Salma Ali Hamad email 4
1Department of Dermatology, Venerology and Andrology
2Department of Dermatology, Venereology and Andrology , Faculty of Medicine, Alexandria University, Egypt.
3Department of Clinical and Chemical Pathology, Faculty of Medicine University of Alexandria.
4Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University.
Abstract
Psoriasis is a chronic illness with long coarse duration wich can affects all age groups and both sexes are equally affected, as other autoimmune disease it characterized by over production of many inflammatory cytokines including IL-6.
Clinically the disease characterized by well demarcated erythematous silvery plaques on affected areas. Psoriasis vulgaris is the most common type of psoriasis which account for 85-95% of all cases.
The disease has no permanent cure, but treatments lines were present to relief the symptoms of disease. There are several adopted modes of treatments available including, topical, UVR, systemic including oral and injectable treatments according to the disease severities.
Methotrexate and Adalimumab are most common systemic treatment in the management of plaque psoriasis with the good clinical response.
AIM OF WORK:
The aim of this study was to assess serum level of IL-6 before and after methotrexate treatment and compared to its level before and after treatment with adalimumab.
Keywords
INTERLEUKIN-6; METHOTREXATE; ADALIMUMAB
Supplementary Files
download 1731 Salma Ali Hamad.pdf
Statistics
Article View: 51
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.